ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Developmental Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1602622
This article is part of the Research TopicInsights in Developmental Endocrinology: 2024View all articles
Predictive Value of Serum Sortilin, HMGB1, and Galanin-like Peptide for Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome
Provisionally accepted
Hui Li*
Xinghao Zhao- Henan Provincial People's Hospital, Zhengzhou, Henan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Polycystic ovary syndrome (PCOS) is associated with increased risk of gestational diabetes mellitus (GDM), but reliable early predictive biomarkers remain lacking. This study investigated the predictive value of serum Sortilin, HMGB1, and galanin-like peptide (GALP) for GDM development in PCOS pregnancies.Methods: This prospective cohort study enrolled 139 PCOS patients. Serum Sortilin, HMGB1 and GALP levels were measured by ELISA at 8-12 weeks. GDM was diagnosed at 24-28 weeks using 75g OGTT (IADPSG criteria). Predictive performance was assessed using multivariable logistic regression and receiver operating characteristic (ROC) curve analysis, with adjustment for maternal age, BMI, and lipid profiles.The PCOS-GDM group (n=60) showed significantly higher levels of all biomarkers versus controls (n=79) (all p<0.001). GALP (aOR=1.55, 95%CI:1.05-1.92) and HMGB1 (aOR=1.65, 95%CI:1.50-1.79) independently predicted GDM after adjustment. The combined model achieved superior prediction (AUC=0.84, 95%CI:0.74-0.94) versus individual markers.Serum GALP and HMGB1 are promising early predictors of GDM in PCOS pregnancies, with combined assessment offering optimal risk stratification. These findings may facilitate timely intervention in high-risk populations.
Keywords: Polycystic Ovary Syndrome, gestational diabetes mellitus, biomarkers, HMGB1, Galanin-Like Peptide
Received: 30 Mar 2025; Accepted: 25 Apr 2025.
Copyright: © 2025 Li and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hui Li, Henan Provincial People's Hospital, Zhengzhou, 450000, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.